EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

被引：0
|
作者：
Panaccione, Remo
Rubin, David T.
Sands, Bruce E.
Reinisch, Walter
D'Haens, Geert
Panes, Julian
Gonzalez, Susana
Weisel, Kathleen
Sahoo, Aparna
Frustaci, Mary Ellen S.
Yang, Zijiang
Sandborn, William J.
Afzali, Anita
Hisamatsu, Tadakazu
Danese, Silvio
Andrews, Jane M.
Feagan, Brian G.
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
888
引用
收藏
页码：S216 / S217
页数：2
相关论文
共 50 条
  • [21] Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Patients With Moderately to Severely Active Crohn's Disease and Inadequate Response to Ustekinumab: Phase 2 GALAXI 1 Study Long-Term Extension Results
    Afzali, Anita
    Wolf, Douglas
    Leong, Rupert
    Salese, Leonardo
    Gao, Long-Long
    Busse, Christopher
    Panes, Julian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1023 - S1024
  • [22] Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
    Danese, Silvio
    Panaccione, Remo
    Feagan, Brian G.
    Afzali, Anita
    Rubin, David T.
    Sands, Bruce E.
    Reinisch, Walter
    Panes, Julian
    Sahoo, Aparna
    Terry, Natalie A.
    Chan, Daphne
    Han, Chenglong
    Frustaci, Mary Ellen
    Yang, Zijiang
    Sandborn, William J.
    Hisamatsu, Tadakazu
    Andrews, Jane M.
    D'Haens, Geert R.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2024, 9 (02): : 133 - 146
  • [23] THE EFFICACY AND SAFETY OF GUSELKUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi
    Huang, Kuan-Hsiang G.
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    Dignass, Axel
    GASTROENTEROLOGY, 2024, 166 (05) : S180 - S180
  • [24] Corticosteroid sparing effects of treatment with guselkumab in patients with moderate to severely active Crohn's disease: Phase 3 GALAXI 2/3 results through week 48
    Panes, J.
    Hisamatsu, T.
    Armuzzi, A.
    Terry, N. A.
    Salese, L.
    Van Rampelbergh, R.
    Yee, J.
    Wan, K. Y.
    Yang, Z.
    Pin, S.
    Sands, B. E.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1724 - i1725
  • [25] Efficacy by baseline disease characteristics of subcutaneous guselkumab induction therapy in patients with moderately to severely active Crohn's disease: Results at Week 12 from the phase 3 GRAVITI study
    D'Haens, G.
    Hisamatsu, T.
    Steinwurz, F.
    Hart, A.
    Liu, W.
    Olurinde, M.
    Ngqawa, P.
    Yang, Z.
    Merrall, E.
    Terry, N. A.
    Sands, B. E.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1608 - I1609
  • [26] Early disease efficacy of guselkumab therapy in biologic-naive patients with moderately to severely active Crohn's disease: Post-hoc analysis from the phase 3 GALAXI 2 & 3 studies
    Afzali, A.
    Rubin, D. T.
    Danese, S.
    Rayyan, Y.
    Chen, M.
    Terry, N. A.
    Salese, L.
    Van Rampelbergh, R.
    Yee, J.
    Gomez, M.
    Wan, K. Y. Y.
    Yang, Z.
    Sands, B. E.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i200 - i201
  • [27] Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn's disease: Phase 3 GRAVITI study results through week 48
    Hart, A.
    Panaccione, R.
    Steinwurz, F.
    Cao, Q.
    Hisamatsu, T.
    Nancey, S.
    Olurinde, M.
    Yang, Z.
    Merrall, E.
    Terry, N. A.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1662 - i1663
  • [28] Efficacy and safety of risankizumab therapy in Chinese patients with moderately to severely active crohn's disease
    Gao, X.
    Cao, Q.
    Ran, Z. H.
    Chen, Y. X.
    Chen, Y.
    Wen, Z. H.
    Liu, D. L.
    Ding, J.
    Zhong, J.
    Liu, F.
    Sha, W. H.
    An, P.
    Wang, B. M.
    Hu, L. X.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1298 - i1299
  • [29] Week 48 Efficacy Of Guselkumab And Ustekinumab In Crohn's Disease Based On Prior Response/Exposure To Biologic Therapy: Results From The GALAXI 2 and 3 Phase 3 Studies
    Danese, Silvio
    Afzali, Anita
    Panaccione, Remo
    Panes, Julian
    Reinisch, Walter
    Terry, Natalie A.
    Salese, Leonardo
    Van Rampelbergh, Rian
    Wan, Kitty Y. Y.
    Yang, Zijiang
    Johanns, Jewel
    Zmudzinski, Marcin
    Zittan, Eran
    Matsuoka, Katsuyoshi
    Jairath, Vipul
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S741 - S742
  • [30] Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease: U-ENDURE Phase 3 Results
    Panes, Julian
    Loftus, Edward, Jr.
    Lacerda, Ana
    Peyrin-Biroulet, Laurent
    D'Haens, Geert
    Panaccione, Remo
    Reinisch, Walter
    Louis, Edouard
    Chen, Minhu
    Nakase, Hiroshi
    Begun, Jakob
    Boland, Brigid
    Liu, Jianzhong
    Dubcenco, Elena
    Mohamed, Mohamed-Eslam
    Feng, Tian
    Colombel, Jean-Frederic
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S10 - S10
12345